# A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part

Source: https://onco.cc/trials/nct07521852/  
OnCo record `nct07521852` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sintilimab in hepatocellular carcinoma, run by TaiRx, Inc., now recruiting.

## Summary

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC is a phase 2 interventional study registered as NCT07521852 by TaiRx, Inc., with 40 participants planned, started 2026-03-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: CVM-1118 + Sintilimab + TACE. Conditions listed: HCC - Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07521852
- Phase: 2
- Setting: A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetic (PK) of CVM-1118 in Combination With Sintilimab and Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
- Sponsor: TaiRx, Inc.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07521852: https://clinicaltrials.gov/study/NCT07521852

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Sintilimab](https://onco.cc/drugs/sintilimab/)

---
JSON: https://onco.cc/api/v1/entities/nct07521852.json